Sana Biotechnology Q4 adjusted EPS misses estimates

Sana Biotechnology, Inc.

Sana Biotechnology, Inc.

SANA

0.00


Overview

  • Biotech firm reported Q4 adjusted EPS miss analyst expectations

  • Raised $133.7 mln from stock sales, cash runway into late 2026


Outlook

  • Sana anticipates cash runway into late 2026


Result Drivers

  • RESEARCH AND DEVELOPMENT EXPENSES: For the three months ended December 31, 2025, research and development expenses, inclusive of non-cash expenses, were $34.9 million


Company press release: ID:nGNX25tq5m


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Adjusted EPS

Miss

-$0.16

-$0.13 (7 Analysts)

Q4 EPS

-$0.21

Q4 Operating Expenses

$61.20 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Sana Biotechnology Inc is $7.50, about 80.7% above its March 2 closing price of $4.15


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.